Investment Of Rs 200 Cr For Medicinal Plant Sector Of NE: Sonowal

Jorhat: Union minister Sarbananda Sonowal on Sunday said investment to the tune of around Rs 200 crore will be made in the CSIR-North East Institute of Science and Technology (NEIST) to build capacity for the medicinal plant sector of the region.

The amount is aimed at creating infrastructure that will boost medicinal plant storage for commercial purpose, strengthen research and development of local herbs and plants for medicinal purpose, as well as provide a platform for traditional healers to further their treatment to a wider section of the society, an official release said.

Sonowal, the Union Minister of Ayush, made the announcement at CSIR-NEIST.

The NEIST at Jorhat, formerly known as Regional Research Laboratory, is a constituent establishment of the Council of Scientific and Industrial Research (CSIR).

“The rich bounty of nature of North East must be used responsibly so that the ecology of the region is sustained, while the medicinal benefits from the herbs can be extracted responsibly to ramp up India’s rich heritage in traditional medicine,” Sonowal said.

“We are revitalising the traditional medicine with a rational approach to scientifically validate its outcome so that more and more people can avail its life-enriching benefit. As India leads the resurgence of traditional medicine globally, the North East will play a crucial role to act as harbinger of growth for the healing industry of India,” he said.

During the visit, the minister reviewed the progress of different activities undertaken by the institute to strengthen the potential of medicinal plant market in the region, the release added.

Related Posts

Spurious drug probe: SIT raids medical store in Bengaluru, detains proprietor

Bengaluru: In a major breakthrough in the illegal pharmaceutical network operating in Karnataka, investigators from the Special Investigation Team (SIT) raided Krupa Health Care at Minerva Circle, seizing a cache…

US FDA grants orphan drug designation for Lundbeck’s investigational anti-ACTH monoclonal antibody asedebart to treat endogenous Cushing’s syndrome

Lundbeck, a biopharmaceutical company focusing exclusively on brain health, announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to asedebart (Lu AG13909), Lundbeck’s novel…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Spurious drug probe: SIT raids medical store in Bengaluru, detains proprietor

Spurious drug probe: SIT raids medical store in Bengaluru, detains proprietor

US FDA grants orphan drug designation for Lundbeck’s investigational anti-ACTH monoclonal antibody asedebart to treat endogenous Cushing’s syndrome

US FDA grants orphan drug designation for Lundbeck’s investigational anti-ACTH monoclonal antibody asedebart to treat endogenous Cushing’s syndrome

Fujifilm India installs Echelon Smart MRI at Jansons Health in Erode

Fujifilm India installs Echelon Smart MRI at Jansons Health in Erode

Rajasthan to prepare ‘Narcotics Control Vision 2026-29’ to curb drug abuse and trafficking

Rajasthan to prepare ‘Narcotics Control Vision 2026-29’ to curb drug abuse and trafficking

Bracco Imaging expands BubbleGen cell selection with CD3+ T Cell Isolation Kit

Bracco Imaging expands BubbleGen cell selection with CD3+ T Cell Isolation Kit

5 medicine samples found substandard in Bhiwadi warehouse raid; probe launched

5 medicine samples found substandard in Bhiwadi warehouse raid; probe launched